Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal

Eli Lilly Acquires Kelonia Therapeutics for Up to $7B to Boost In Vivo CAR T

Eli Lilly is set to acquire Kelonia Therapeutics for up to $7 billion, including an upfront payment of $3.25 billion, significantly bolstering its presence in the *in vivo* CAR T therapy space. The acquisition includes Kelonia's Phase 1 lentiviral *in vivo* CAR-T therapy, KLN-1010, and its proprietary iGPS gene delivery and integration technology. The iGPS platform aims to revolutionize CAR T manufacturing by using lentiviral-based particles to deliver T-cells, enabling the patient's body to generate its own CAR T therapies, thereby potentially eliminating complex ex vivo manufacturing and pre-treatment chemotherapy. KLN-1010 is currently being developed for multiple myeloma.

• Eli Lilly's acquisition of Kelonia Therapeutics, valued at up to $7 billion, represents a strategic expansion into in vivo CAR-T therapy. The core asset is Kelonia's iGPS gene delivery and integration technology, which utilizes lentiviral-based particles to deliver T-cells. This innovative platform aims to enable the patient's body to generate its own CAR T therapies, potentially streamlining the process by eliminating the need for complex ex vivo manufacturing and pre-treatment chemotherapy.
• The deal encompasses KLN-1010, a Phase 1 lentiviral in vivo CAR-T therapy specifically targeting multiple myeloma. Early data from an early-stage trial, presented at the American Society of Hematology, provided initial validation for the iGPS technology's viability and demonstrated tolerability, alongside impressive early responses. This clinical progress underscores the potential of Kelonia's approach in addressing a challenging hematological malignancy.
• Financially, Lilly will provide an upfront payment of $3.25 billion to Kelonia shareholders, with additional payments contingent upon the achievement of certain milestones. This acquisition marks Lilly's second significant move in the CAR T space this year, following the $2.4 billion acquisition of Orna Therapeutics, further solidifying its commitment to genetic medicines and oncology. The transaction is anticipated to close in the second half of 2026.

The Persistent Challenges in Multiple Myeloma Therapy

Despite significant therapeutic advances, multiple myeloma continues to present formidable treatment challenges for clinicians and patients. The disease remains incurable even with expanded treatment options and highly effective therapeutics, with drug resistance and relapse representing the primary obstacles to long-term disease control.

• Drug resistance and clonal evolution remain the most problematic aspects of MM treatment, with patients frequently developing resistance and becoming refractory to standard therapies, including all major drug classes such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies

• Treatment complexity and selection challenges have increased due to the vast array of available drug combinations and novel therapeutic options, particularly in relapsed/refractory MM, making optimal treatment selection increasingly difficult for clinicians

• Disease heterogeneity necessitates personalized testing tools to identify individual drug sensitivities, as the varied nature of MM requires tailored approaches rather than one-size-fits-all treatment strategies

• Economic accessibility remains a significant barrier, as novel therapies for multiple myeloma are not affordable for all healthcare systems, limiting patient access to potentially life-saving treatments

• Genetic and molecular factors negatively impact treatment outcomes, including the presence of extramedullary disease, t(14;16) translocation, chromosome 13 deletion, and gain(1q21), which is associated with low sensitivity to venetoclax

• Emerging therapy limitations persist, as the effectiveness of newer approaches like CAR-NK cell therapy in eliminating MM remains to be fully established, and novel therapeutic agents are still needed to address fundamental issues of drug resistance and clonal evolution

• Treatment decision complexity in relapsed/refractory MM requires consideration of multiple factors including biochemical markers, disease dynamics, prior therapy lines, toxicity profiles, and underlying health status, necessitating shared decision-making approaches

Transforming CAR T: Lilly's Leap into In Vivo Gene Delivery

The landscape of hematologic malignancy treatment has been profoundly reshaped by chimeric antigen receptor T-cell (CAR T) therapy, offering a personalized immunotherapy approach that has delivered robust responses in conditions like multiple myeloma. However, the widespread adoption and accessibility of these life-saving treatments have been hampered by a confluence of challenges. Current ex vivo CAR T manufacturing is a complex, multi-step process, often leading to significant delays, high costs, and logistical hurdles for both healthcare systems and patients. These issues contribute to inequities in access and place a substantial financial burden on health systems globally.

Eli Lilly's acquisition of Kelonia Therapeutics signals a bold strategic move to address these fundamental limitations head-on. By investing in Kelonia's in vivo CAR T technology, particularly the iGPS gene delivery platform, Lilly is betting on a future where CAR T therapy can be generated directly within the patient's body. This innovative approach aims to eliminate the need for intricate ex vivo cell processing and potentially bypass pre-treatment chemotherapy, which are major contributors to the current therapy's complexity, cost, and patient burden.

This shift could unlock several critical advantages:

• Expanded Access: By simplifying the treatment pathway, in vivo CAR T could make these therapies available to a much broader patient population, including those in settings with limited specialized infrastructure.

• Reduced Costs and Delays: Streamlining or eliminating ex vivo manufacturing steps could significantly lower overall treatment costs and reduce the lengthy wait times currently associated with CAR T production.

• Enhanced Patient Experience: Removing the need for ex vivo manipulation and potentially pre-treatment chemotherapy could reduce the physical and logistical burden on patients, who currently face long hospital stays and a range of potential toxicities.

However, this promising frontier is not without its inherent risks. The in vivo approach must rigorously demonstrate efficacy and safety profiles that are at least comparable to, if not superior to, existing ex vivo CAR T therapies. These established treatments are known to cause significant adverse events, including cytokine release syndrome and various forms of neurotoxicity, which require careful management. Furthermore, while the in vivo method aims to simplify manufacturing, it introduces novel challenges related to the precise and consistent delivery and integration of genetic material within the patient. Finally, even with an in vivo approach, the biological complexities of cancer, such as tumor antigen loss, T-cell exhaustion, and the emergence of extramedullary disease, which contribute to relapse in ex vivo CAR T, will likely remain critical factors influencing long-term durability and patient outcomes. Lilly's investment underscores a commitment to innovation that could redefine the future of cell therapy, but its success hinges on overcoming these substantial scientific and clinical hurdles.